Industry Insight

Forward-looking Investment Opportunities

Gain exposure to a diversified portfolio of companies

Early Stage

Early-stage gene editing companies: Early-stage companies developing gene editing therapies for a variety of diseases. If a company is successful in developing a new gene editing therapy that is approved by the FDA and reaches the market, it could generate significant revenue for investors.

Personalized Therapies

Personalized cancer therapy companies. These therapies are tailored to the individual patient's genetic and other data, and they have the potential to be more effective and less toxic than traditional cancer treatments.


RNAi drug companies are all developing RNAi drugs. RNAi drugs have the potential to treat a wide range of diseases, including cancer, viral infections, and neurological disorders.

Cell & Gene

Cell and gene therapy companies are all developing cell and gene therapies for a variety of diseases. Cell and gene therapies are highly complex and expensive to develop and manufacture, but they have the potential to cure some diseases that are currently untreatable.

Capitalizing on Advanced Medical Researches

Looking into both early-stage and more established companies that are developing or commercializing new drugs and technologies

Nanoparticle Drug

Investing in nanoparticle drug companies: BIND Therapeutics, NanOvation Sciences, and Calando Pharmaceuticals are all developing nanoparticle-based drugs. Nanoparticle drugs have the potential to improve the efficacy and safety of many drugs, but they are still in the early stages of development.

Protein-Protein Interaction

Investing in drug companies that target protein-protein interactions: Arvinas Therapeutics, C4 Therapeutics, and Protagonist Therapeutics are all developing drugs that target protein-protein interactions. Protein-protein interactions play a role in many diseases, but they are difficult to target with traditional drugs.

Latest Tech

Investing in companies that are developing new technologies and services to support the development and commercialization of new drugs. For example, Opaca could invest in companies that develop new drug discovery tools, clinical trial management software, or patient support services.